针对B细胞恶性瘤中的BTK:从作用方式到抵抗机制
Samir Mouhssine1, Nawar Maher1, Bassam Francis Matti2
1Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy.
International journal of molecular sciences
|March 28, 2024
概括
布鲁顿氨酸激酶 (BTK) 抑制剂对B细胞恶性瘤有效,但可能发生耐药性. 正在开发非共价抑制剂和PROTAC等新策略,以克服BTK抑制剂耐药性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- B细胞受体 (BCR) 信号通路对B细胞发育至关重要,并与B细胞瘤有关.
- 恶性瘤中的构成性BCR活性导致持续的布鲁顿氨酸激酶 (BTK) 信号发送,促进癌细胞的存活和增殖.
- BTK 抑制剂 (BTKi) 在慢性淋巴细胞白血病,地幔细胞淋巴瘤和扩散大B细胞淋巴瘤中显示出有效性.
研究的目的:
- 审查B细胞恶性瘤中对共价BTK抑制剂 (BTKi) 的耐药性机制.
- 讨论克服BTKi耐药性的新兴策略,包括非共价抑制剂和PROTACs.
主要方法:
- 对B细胞恶性瘤中BTK信号传递研究的文献综述.
- 对共价BTKi的抗性机制的分析,例如Cys-481突变.
- 对针对BTK的新型治疗策略的评估.
主要成果:
- 同价BTKi通过与Cys-481结合,不可逆地抑制BTK,但在很大一部分患者中会产生耐药性.
- 在Cys-481中发生的突变是对共价BTKi耐药性的关键机制.
- 非共价BTKi (例如,皮尔托布鲁替尼) 和BTK向的PROTAC在克服抗药性方面表现有前途.
结论:
- 尽管存在耐药性的挑战,BTK仍然是B细胞恶性瘤的关键目标.
- 非共价BTKi和PROTAC的开发为耐药性疾病患者提供了新的治疗途径.
- 有效地准BTK对于改善B细胞瘤的结果至关重要.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cytotoxic T Cells-mediated Immune Response
907
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
907
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K


